<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content

Using Champions’ PDX models for preclinical validation of HER2-specific small molecule inhibitors

A Champions Case Study

HER2/neu (encoded by ERBB2 in humans) is a member of the HER/EGFR family of tyrosine kinase receptors that facilitates the translation of extracellular signals into cellular outputs such as growth and proliferation.

In cooperation with the scientific experts at Champions Oncology, our client selected a panel of HER2-amplified breast models, as well as additional HER2-amplified models from our colorectal and esophageal cohorts for indication expansion. 

This case study explores how to preclinically validate HER2-specific small molecule inhibitors using Champions' PDX models. 

Download the Case Study